Last reviewed · How we verify

NCT03694691

Developing Viability Index for Machine Perfused Livers

Recruiting now NA Last updated 3 November 2025
What this trial tests

NA trial testing Liver Biopsy in Liver Cirrhoses in 60 participants. Currently enrolling.

Timeline
1 October 2018
Primary endpoint
1 December 2028
1 June 2030

Quick facts

Lead sponsorMassachusetts General Hospital
PhaseNA
StatusRecruiting now
Study typeINTERVENTIONAL
Allocationna
Designsingle group
Maskingnone
Primary purposediagnostic
Enrollment60
Start date1 October 2018
Primary completion1 December 2028
Estimated completion1 June 2030
Sites1 location across United States

Drugs / interventions tested

Conditions studied

Sponsor

Massachusetts General Hospital

Who can join

Adults 18 to 75, any sex, with Liver Cirrhoses. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Machine perfusion technology is nearing the point of rescuing discarded liver grafts in the hope of proving them to be or improving them to the point of being transplantable. However, there are no validated metrics to determine transplantability after machine perfusion. This study involves collecting biopsies from transplanted livers before and after implantation to correlate metabolite and gene expression with post-transplant function. This data will help develop a viability index for machine perfused livers.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Liver Biopsy

Trials testing the same drug.

Other recruiting trials for Liver Cirrhoses

Currently open trials in the same condition.

Other Massachusetts General Hospital trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03694691.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing